Genetic Engineering in Diabetes: Recombinant Insulin, Gene Therapy, and Xenotransplantation

Genetic engineering has revolutionized diabetes care and holds future promise.

Current Applications

  1. Recombinant human insulin: Produced in E. coli or yeast since 1982; identical to human insulin; replaced animal insulins.
  2. Insulin analogs: Engineered amino acid substitutions → rapid-acting (lispro, aspart, glulisine) or long-acting (glargine, detemir, degludec) profiles.
  3. Advanced delivery: Insulin pumps, closed-loop “artificial pancreas” systems using CGM algorithms.

Emerging Therapies

  • Gene therapy: Viral (AAV) or non-viral delivery of insulin/transcription factors to hepatocytes or pancreatic progenitors to restore endogenous production.
  • Cell replacement: Stem cell-derived beta cells (e.g., Vertex VX-880) encapsulated or gene-edited for immune evasion.
  • Xenotransplantation: CRISPR-edited pig islets (knockout of GGTA1, CMAH, β4Gal, + human transgenes) for unlimited supply.
  • Disease modeling: iPSCs from patients with monogenic diabetes (MODY, neonatal) for drug screening.
  • Personalized medicine: Pharmacogenomics (e.g., TCF7L2, KCNJ11) guiding sulfonylurea vs. insulin choice.

Most are in clinical trials; recombinant insulin/analogs are standard of care today.

Genetic Disorders - Related Articles